Clinical Activity and Safety of KT-621, an Oral STAT6 Degrader, in Moderate-to-Severe Atopic Dermatitis: Phase 1b Trial Results

Clinical Activity and Safety of KT-621, an Oral STAT6 Degrader, in Moderate-to-Severe Atopic Dermatitis: Phase 1b Trial Results

American Academy of Dermatology (AAD) 2026 – Late Breaking Oral Presentation

Jared Gollob,¹ Heather Paleczny,¹ Michael Blankinship,² Paul Yamauchi,³ Vlada Groysman,⁴ Neil Graham,¹ Joyoti Dey,¹ Sagar Agarwal,¹ Kelvin Shi,¹ Mahta Mortezavi,¹ Nello Mainolfi¹

¹Kymera Therapeutics, Inc., Watertown, MA, USA; ²Red River Research Partners, Fargo, ND, USA; ³Clinical Science Institute, Santa Monica, CA, USA; ⁴Cahaba Dermatology & Skin Health Center, Birmingham, AL, USA